Hookipa Pharma (HOOK) News Today → “Dollar Will Be Worth NOTHING” -Musk (From Crypto 101 Media) (Ad) Free HOOK Stock Alerts $0.82 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 2:27 PM | investorplace.comPenny Stock Sleepers: 7 Under-the-Radar Gems Ready to LaunchMay 13, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Short Interest Up 103.3% in AprilHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) was the recipient of a large growth in short interest in April. As of April 30th, there was short interest totalling 643,700 shares, a growth of 103.3% from the April 15th total of 316,700 shares. Approximately 0.9% of the company's shares are short sold. Based on an average daily volume of 782,800 shares, the short-interest ratio is presently 0.8 days.May 11, 2024 | finance.yahoo.comHOOKIPA Pharma First Quarter 2024 Earnings: Beats ExpectationsMay 10, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Announces Quarterly Earnings ResultsHookipa Pharma (NASDAQ:HOOK - Get Free Report) issued its earnings results on Thursday. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.24. The company had revenue of $36.60 million during the quarter, compared to analyst estimates of $3.20 million. Hookipa Pharma had a negative return on equity of 72.30% and a negative net margin of 405.28%. During the same quarter last year, the business posted ($0.27) EPS.May 9, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 9, 2024 | globenewswire.comHOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business HighlightsMay 8, 2024 | marketbeat.comHookipa Pharma (HOOK) Scheduled to Post Quarterly Earnings on ThursdayHookipa Pharma (NASDAQ:HOOK) will be releasing earnings before the market opens on Thursday, May 9, Zacks reports.April 27, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 26, 2024 | markets.businessinsider.comBreaking Down HOOKIPA Pharma: 4 Analysts Share Their ViewsApril 25, 2024 | globenewswire.comHOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with PembrolizumabApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma Amidst Promising Pipeline and Strategic AdvancementsApril 24, 2024 | globenewswire.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated CancersApril 17, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 16, 2024 | finance.yahoo.comHOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | globenewswire.comHOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to RegistrationApril 1, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Sees Significant Growth in Short InterestHookipa Pharma Inc (NASDAQ:HOOK - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 333,400 shares, a growth of 11.3% from the February 29th total of 299,500 shares. Based on an average daily trading volume, of 2,410,000 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.6% of the shares of the company are sold short.March 27, 2024 | markets.businessinsider.comOptimistic Buy Rating for Hookipa Pharma Based on Promising HB-200 Trial Results and Strategic Trial DesignMarch 26, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Expected to Post FY2028 Earnings of $0.31 Per ShareHookipa Pharma Inc (NASDAQ:HOOK - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 EPS estimates for Hookipa Pharma in a note issued to investors on Monday, March 25th. HC Wainwright analyst A. He expects that the company will post earnings of $0.31 per share for theMarch 25, 2024 | marketbeat.comHookipa Pharma's (HOOK) "Outperform" Rating Reaffirmed at Royal Bank of CanadaRoyal Bank of Canada reiterated an "outperform" rating and set a $5.00 price objective on shares of Hookipa Pharma in a report on Monday.March 24, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 24, 2024 | finance.yahoo.comTime To Worry? Analysts Just Downgraded Their HOOKIPA Pharma Inc. (NASDAQ:HOOK) OutlookMarch 23, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK), Earnings Estimates, EPS, and RevenueMarch 23, 2024 | markets.businessinsider.comBuy Rating Affirmed for Hookipa Pharma on Emerging Oncology and Infectious Disease PipelinesMarch 22, 2024 | msn.comHOOKIPA Pharma GAAP EPS of -$0.22 misses by $0.02, revenue of $7.41M beats by $2.85MMarch 22, 2024 | globenewswire.comHOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business HighlightsMarch 6, 2024 | globenewswire.comHOOKIPA Pharma to Participate in Leerink Partners Global Biopharma ConferenceMarch 1, 2024 | marketbeat.comHookipa Pharma (NASDAQ:HOOK) Stock Price Down 4%Hookipa Pharma (NASDAQ:HOOK) Trading Down 4%February 28, 2024 | morningstar.comHOOKIPA Pharma Inc HOOKFebruary 22, 2024 | benzinga.comHOOKIPA Pharma Stock (NASDAQ:HOOK) Dividends: History, Yield and DatesFebruary 2, 2024 | finance.yahoo.comAll You Need to Know About HOOKIPA Pharma Inc. (HOOK) Rating Upgrade to Strong BuyFebruary 1, 2024 | markets.businessinsider.comMaintaining Buy Rating on Hookipa Pharma Amid Strategic Repositioning and Pipeline PromiseFebruary 1, 2024 | marketbeat.comHookipa Pharma Inc (NASDAQ:HOOK) Forecasted to Post FY2024 Earnings of ($0.27) Per ShareHookipa Pharma Inc (NASDAQ:HOOK - Free Report) - Equities researchers at Leerink Partnrs raised their FY2024 EPS estimates for Hookipa Pharma in a report released on Monday, January 29th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.27) per share foJanuary 31, 2024 | uk.investing.comHookipa Pharma Inc (HOOK)January 30, 2024 | marketbeat.comRoyal Bank of Canada Lowers Hookipa Pharma (NASDAQ:HOOK) Price Target to $5.00Royal Bank of Canada lowered their target price on shares of Hookipa Pharma from $6.00 to $5.00 and set an "outperform" rating for the company in a research note on Tuesday.January 29, 2024 | markets.businessinsider.comStrategic Focus on Promising HPV+ Cancer Candidate Underpins Buy Rating for Hookipa PharmaJanuary 29, 2024 | markets.businessinsider.comHOOKIPA Pharma To Cut Jobs Following Collaboration Termination By RocheJanuary 29, 2024 | msn.comRoche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer DealJanuary 29, 2024 | marketwatch.comHOOKIPA Pharma Shares Fall Premarket as Roche Ends CollaborationJanuary 16, 2024 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationJanuary 16, 2024 | finance.yahoo.comHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationJanuary 16, 2024 | finance.yahoo.comHOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development OrganizationDecember 22, 2023 | finanznachrichten.deHOOKIPA Pharma Inc.: HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesDecember 22, 2023 | msn.comHOOKIPA Pharma files to sell 15M shares for holdersDecember 22, 2023 | ca.finance.yahoo.comHOOKIPA Pharma Inc. (HOOK)December 21, 2023 | marketwatch.comHOOKIPA Pharma Shares Soar After Gilead Sciences InvestmentDecember 21, 2023 | finance.yahoo.comHOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead SciencesDecember 21, 2023 | investorplace.comWhy Is Hookipa Pharma (HOOK) Stock Up 81% Today?November 20, 2023 | markets.businessinsider.comHOOKIPA Pharma: HB-500 IND Application Gets FDA Clearance To Treat HIVNovember 20, 2023 | finance.yahoo.comHOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency VirusNovember 12, 2023 | markets.businessinsider.comPromising Clinical Trials and Strong Financial Performance Bolster Buy Rating for Hookipa Pharma Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address [FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks (Ad)Are you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealthy beyond your wildest dreams. You see, while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. HOOK Media Mentions By Week HOOK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HOOK News Sentiment▼0.740.54▲Average Medical News Sentiment HOOK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HOOK Articles This Week▼51▲HOOK Articles Average Week Get Hookipa Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for HOOK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Jaguar Health News Today Corvus Pharmaceuticals News Today LifeVantage News Today Tempest Therapeutics News Today Connect Biopharma News Today Affimed News Today Leap Therapeutics News Today Reviva Pharmaceuticals News Today Anebulo Pharmaceuticals News Today Marinus Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HOOK) was last updated on 5/17/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportWhy Is Gold On a MASSIVE rally? Huge AlertsGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchDems have chosen Biden replacement?Paradigm PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaThe #1 Investment of the Decade… Porter & Company[URGENT] DO NOT Touch These AI Stocks!Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hookipa Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
